Theranostics 2019; 9(16):4595-4596. doi:10.7150/thno.36746 This issue Cite

Erratum

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum

Maximilian Klingler1, Clemens Decristoforo1, Christine Rangger1, Dominik Summer1, Julie Foster2, Jane K Sosabowski2, Elisabeth von Guggenberg1 Corresponding address

1. Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
2. Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Citation:
Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum. Theranostics 2019; 9(16):4595-4596. doi:10.7150/thno.36746. https://www.thno.org/v09p4595.htm
Other styles

File import instruction

Corrected-article in Theranostics, Volume 8, 2896

 

In our paper [1] unfortunately an error occurred in Figure 1. We therefore would like to provide the readers with the corrected figure and apologize for this inconvenience.

 Figure 1 

Structure of A) DOTA-MG11, B) DOTA-MGS1, C) DOTA-MGS2, D) DOTA-MGS3, E) DOTA-MGS4; R = DOTA-DGlu-Ala-Tyr-Gly.

Theranostics Image

References

1. Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting. Theranostics. 2018;8(11):2896-2908

Author contact

Corresponding address Corresponding author: E-mail: elisabeth.von-guggenbergac.at; Tel: +4351250480960; Fax: +435125046780960


Published 2019-6-19


Citation styles

APA
Klingler, M., Decristoforo, C., Rangger, C., Summer, D., Foster, J., Sosabowski, J.K., von Guggenberg, E. (2019). Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum. Theranostics, 9(16), 4595-4596. https://doi.org/10.7150/thno.36746.

ACS
Klingler, M.; Decristoforo, C.; Rangger, C.; Summer, D.; Foster, J.; Sosabowski, J.K.; von Guggenberg, E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum. Theranostics 2019, 9 (16), 4595-4596. DOI: 10.7150/thno.36746.

NLM
Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum. Theranostics 2019; 9(16):4595-4596. doi:10.7150/thno.36746. https://www.thno.org/v09p4595.htm

CSE
Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. 2019. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum. Theranostics. 9(16):4595-4596.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image